- Generic injectables, offering fast-acting and cost-effective treatments, are increasingly vital components in the global fight against infectious diseases across inpatient and outpatient settings, owing to their broad-spectrum efficacy, affordability, and critical role in antimicrobial and antiviral therapies
- The escalating demand for generic injectables is primarily fueled by the rising global burden of infectious diseases, healthcare cost-containment pressures, and increased adoption of generics by hospitals and public health systems for emergency preparedness and routine treatment
- North America dominated the generic injectables for infectious diseases market with the largest revenue share of 39.5% in 2024, driven by strong regulatory support, high generic penetration, and a mature pharmaceutical supply chain, with the U.S. showing increased reliance on injectable generics for hospital-acquired infections and outpatient parenteral antimicrobial therapy (OPAT)
- Asia-Pacific is expected to be the fastest growing region in the market during the forecast period due to expanding healthcare access, increased production capacity of generics, and a rising prevalence of infectious diseases in densely populated regions
- Small Molecule segment dominated the market with a market share of 42.8% in 2024, driven by their widespread use in treating bacterial infections, cost-efficiency, and critical inclusion in global health procurement programs and hospital formularies
